Metabolic syndrome after hormone-modifying therapy: Risks associated with antineoplastic therapy

ONCOLOGY

Volumn 24, Issue 9, 2010, Pages

  Redig, Amanda J ^a   Munshi, Hidayatullah G ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFINITOR; AROMATASE INHIBITOR; BEVACIZUMAB; BLEOMYCIN; CISPLATIN; ETOPOSIDE; EVEROLIMUS; IMATINIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINBLASTINE;

ANDROGEN DEPRIVATION THERAPY; BREAST CANCER; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; FATTY LIVER; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INSULIN SENSITIVITY; KIDNEY CARCINOMA; LIPID BLOOD LEVEL; LIPID STORAGE; METABOLIC DISORDER; OBESITY; OVARIECTOMY; OVARY CANCER; PROSTATE CANCER; REVIEW; SIDE EFFECT; TESTIS CANCER;

EID: 77958034196     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Wille E, Scholze J, Alegria E, et al: Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy. Eur J Health Econ Apr 20 2010. [Epub ahead of print.] DOI 10.1007/s10198-010-0223-9.
2. Park YW, Zhu S, Palaniappan L, et al: The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163:427-436, 2003.
3. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 287:356-359, 2002. (Pubitemid 34251969)
4. Pothiwala P, Jain SK, Yaturu S: Metabolic syndrome and cancer. Metab Syndr Relat Disord 7:279-288, 2009.
5. Solymoss BC, Bourassa MG, Marcil M, et al: Long-term rates of cardiovascular events in patients with the metabolic syndrome according to severity of coronary-angiographic alterations. Coron Artery Dis 20:1-8, 2009.
6. Boppidi H, Daram SR: Nonalcoholic fatty liver disease: Hepatic manifestation of obesity and the metabolic syndrome. Postgrad Med 120:E01-E07, 2008.
7. De Bruyne RM, Fitzpatrick E, Dhawan A: Fatty liver disease in children: Eat now pay later. Hepatol Int 4:375-385, 2010.
8. Keating NL, OMalley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448-4456, 2006.
9. Cuppone F, Bria E, Verma S, et al: Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 112:260-267, 2008.
10. Castaneda E, Perez AE, Guillen MA, et al: Metabolic studies in a patient with testicular feminization syndrome. Am J Obstet Gynecol 110:1002-1007, 1971.
11. Wortsman J, Soler NG: Abnormalities of fuel metabolism in the polycystic ovary syndrome. Obstet Gynecol 60:342-345, 1982.
12. Cupisti S, Kajaia N, Dittrich R, et al: Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol 158:711-719, 2008. (Pubitemid 351639610)
13. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO: Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 95:136-147, 2006.
14. DAmico AV, Renshaw AA, Loffredo B, Chen MH: Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 110:1723-1728, 2007.
15. Denham JW, Steigler A, Lamb DS, et al: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841-850, 2005.
16. Tsai HK, DAmico AV, Sadetsky N, et al: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516-1524, 2007. (Pubitemid 351767235)
17. Saigal CS, Gore JL, Krupski TL, et al: Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110:1493-1500, 2007.
18. Braga-Basaria M, Dobs AS, Muller DC, et al: Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24:3979-3983, 2006. (Pubitemid 46630747)
19. Traish AM, Saad F, Feeley RJ, Guay AT: The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 30:477-494, 2009.
20. Lage MJ, Barber BL, Markus RA: Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70:1104-1108, 2007.
21. Basaria S, Muller DC, Carducci MA, et al: Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106:581-588, 2006.
22. Traish AM, Saad F, Guay A: The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 30:23-32, 2009.
23. Smith MR, Lee H, Fallon MA, Nathan DM: Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 71:318-322, 2008. (Pubitemid 351282338)
24. Derweesh IH, Diblasio CJ, Kincade MC, et al: Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 100:1060-1065, 2007.
25. Herrington DM, Klein KP: Cardiovascular trials of estrogen replacement therapy. Ann N Y Acad Sci 949:153-162, 2001. (Pubitemid 34059972)
26. Love RR, Wiebe DA, Newcomb PA, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115:860-864, 1991.
27. Dewar JA, Horobin JM, Preece PE, et al: Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 305:225-226, 1992.
28. Saarto T, Blomqvist C, Ehnholm C, et al: Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. J Clin Endocrinol Metab 81:4453-4457, 1996. (Pubitemid 26412060)
29. McDonald CC, Alexander FE, Whyte BW, et al: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 311:977-980, 1995.
30. Early Breast Cancer Trialists Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.
31. Arimidex, Tamoxifen, Alone or in Combination Trialists Group, Buzdar A, Howell A, et al: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 7:633-643, 2006.
32. Coates AS, Keshaviah A, Thurlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007. (Pubitemid 350002953)
33. Mouridsen H, Keshaviah A, Coates AS, et al: Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial. J Clin Oncol 25:5715-5722, 2007.
34. Thurlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005.
35. Ahmed MH, Saad RA, Osman MM: Ezetimibe: Effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: Simvastatin and ezetimibe: Combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother 6:131-139, 2005. Expert Opin Drug Saf 5:487-488, 2006.
36. Nguyen MC, Stewart RB, Banerji MA, et al: Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord 25:296-298, 2001. (Pubitemid 33593532)
37. Bruno S, Maisonneuve P, Castellana P, et al: Incidence and risk factors for non-alcoholic steatohepatitis: Prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 330:932, 2005.
38. Dørum A, Tonstad S, Liavaag AH, et al: Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: A controlled, population-based study (HUNT-2). Gynecol Oncol 109:377-383, 2008.
39. Michelsen TM, Pripp AH, Tonstad S, et al: Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: A controlled observational study. Eur J Cancer 45:82-89, 2009.
40. American Cancer Society: Cancer facts & figures 2010. Available at http://www.cancer.org/acs/groups/content/@nho/ documents/document/acspc-024113. pdf. Accessed July 16, 2010.
41. Nuver J, Smit AJ, Wolffenbuttel BH, et al: The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 23:3718-3725, 2005. (Pubitemid 46252467)
42. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513-1523, 2003. (Pubitemid 46594104)
43. Sagstuen H, Aass N, Fossa SD, et al: Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 23:4980-4990, 2005.
44. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725-1732, 2000.
45. Haugnes HS, Aass N, Fossa SD, et al: Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv 2:128-137, 2008.
46. van den Belt-Dusebout AW, Nuver J, de Wit R, et al: Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24:467-475, 2006.
47. Raghavan D, Cox K, Childs A, et al: Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 10:1386-1389, 1992.
48. Nord C, Fossa SD, Egeland T: Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer 88:36-41, 2003. (Pubitemid 36241215)
49. Haugnes HS, Aass N, Fossa SD, et al: Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 18:241-248, 2007. (Pubitemid 46323088)
50. Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671-688, 2006.
51. Rodriguez-Pascual J, Cheng E, Maroto P, Duran I: Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 21:478-486, 2010.
52. Kwitkowski VE, Prowell TM, Ibrahim A,: FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15:428-435, 2010.
53. Bellmunt J, Szczylik C, Feingold J, et al: Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19:1387-1392, 2008.
54. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008.
55. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006.
56. Clark JW, Eder JP, Ryan D, et al: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472-5480, 2005.
57. Guevremont C, Alasker A, Karakiewicz PI: Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care 3:170-179, 2009.
58. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003.
59. DAmico AV, Denham JW, Bolla M, et al: Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer 109:2004-2010, 2007.